Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC

Executive Summary

GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.

Advertisement

Related Content

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
Rhinocort Switch Makes Three In OTC Intranasal Corticosteroid Market
In Brief: GSK, Bristol/Pfizer See Approvals, Baxter Holds Its Own in Hemophilia

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel